92 related articles for article (PubMed ID: 29665649)
1. Subcellular localization of Klf4 in non-small cell lung cancer and its clinical significance.
Liu M; Li X; Peng KZ; Gao T; Cui Y; Ma N; Zhou Y; Hou G
Biomed Pharmacother; 2018 Mar; 99():480-485. PubMed ID: 29665649
[TBL] [Abstract][Full Text] [Related]
2. [Correlation of KLF4 and SPARC expression with the clinical characteristics of non-small cell lung cancer].
Zhang Z; Wang Z; Liu X; Shi M; Chen G; Zhang B; Li Z; Song L
Zhongguo Fei Ai Za Zhi; 2012 Dec; 15(12):720-4. PubMed ID: 23249717
[TBL] [Abstract][Full Text] [Related]
3. Nuclear and cytoplasmic death receptor 5 as prognostic factors in patients with non-small cell lung cancer treated with chemotherapy.
Leithner K; Stacher E; Wurm R; Ploner F; Quehenberger F; Wohlkoenig C; Bálint Z; Polachova J; Olschewski A; Samonigg H; Popper HH; Olschewski H
Lung Cancer; 2009 Jul; 65(1):98-104. PubMed ID: 19081160
[TBL] [Abstract][Full Text] [Related]
4. [Role of SOX4 on DDP Resistance in Non-small Cell Lung Cancer Cell of A549].
Li W; Liu X; Zhang G; Zhang L
Zhongguo Fei Ai Za Zhi; 2017 May; 20(5):298-302. PubMed ID: 28532536
[TBL] [Abstract][Full Text] [Related]
5. KLF4 downregulates hTERT expression and telomerase activity to inhibit lung carcinoma growth.
Hu W; Jia Y; Xiao X; Lv K; Chen Y; Wang L; Luo X; Liu T; Li W; Li Y; Zhang C; Yu Z; Huang W; Sun B; Deng WG
Oncotarget; 2016 Aug; 7(33):52870-52887. PubMed ID: 27153563
[TBL] [Abstract][Full Text] [Related]
6. Glibenclamide Targets Sulfonylurea Receptor 1 to Inhibit p70S6K Activity and Upregulate KLF4 Expression to Suppress Non-Small Cell Lung Carcinoma.
Xu K; Sun G; Li M; Chen H; Zhang Z; Qian X; Li P; Xu L; Huang W; Wang X
Mol Cancer Ther; 2019 Nov; 18(11):2085-2096. PubMed ID: 31341030
[TBL] [Abstract][Full Text] [Related]
7. EHD1 confers resistance to cisplatin in non-small cell lung cancer by regulating intracellular cisplatin concentrations.
Gao J; Meng Q; Zhao Y; Chen X; Cai L
BMC Cancer; 2016 Jul; 16():470. PubMed ID: 27411790
[TBL] [Abstract][Full Text] [Related]
8. [Correlation of P27 expression and localization to phosphorylated AKT in non-small cell lung cancer].
Miao LJ; Wang J; Li SS; Wu YM; Wu YJ; Wang XC
Ai Zheng; 2006 Oct; 25(10):1216-20. PubMed ID: 17059763
[TBL] [Abstract][Full Text] [Related]
9. CXCR4 promotes cisplatin-resistance of non-small cell lung cancer in a CYP1B1-dependent manner.
Xie S; Tu Z; Xiong J; Kang G; Zhao L; Hu W; Tan H; Tembo KM; Ding Q; Deng X; Huang J; Zhang Q
Oncol Rep; 2017 Feb; 37(2):921-928. PubMed ID: 27922681
[TBL] [Abstract][Full Text] [Related]
10. Expression of Ras-related protein 25 predicts chemotherapy resistance and prognosis in advanced non-small cell lung cancer.
Ma YF; Yang B; Li J; Zhang T; Guo JT; Chen L; Li M; Chu J; Liang CY; Liu Y
Genet Mol Res; 2015 Oct; 14(4):13998-4008. PubMed ID: 26535714
[TBL] [Abstract][Full Text] [Related]
11. The deubiquitinase USP10 regulates KLF4 stability and suppresses lung tumorigenesis.
Wang X; Xia S; Li H; Wang X; Li C; Chao Y; Zhang L; Han C
Cell Death Differ; 2020 Jun; 27(6):1747-1764. PubMed ID: 31748695
[TBL] [Abstract][Full Text] [Related]
12. Association of nuclear YB-1 localization with lung resistance-related protein and epidermal growth factor receptor expression in lung cancer.
Hyogotani A; Ito K; Yoshida K; Izumi H; Kohno K; Amano J
Clin Lung Cancer; 2012 Sep; 13(5):375-84. PubMed ID: 22284440
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA-218 regulates cisplatin (DPP) chemosensitivity in non-small cell lung cancer by targeting RUNX2.
Xie J; Yu F; Li D; Zhu X; Zhang X; Lv Z
Tumour Biol; 2016 Jan; 37(1):1197-204. PubMed ID: 26282001
[TBL] [Abstract][Full Text] [Related]
14. Nuclear β-catenin accumulation is associated with increased expression of Nanog protein and predicts poor prognosis of non-small cell lung cancer.
Li XQ; Yang XL; Zhang G; Wu SP; Deng XB; Xiao SJ; Liu QZ; Yao KT; Xiao GH
J Transl Med; 2013 May; 11():114. PubMed ID: 23648139
[TBL] [Abstract][Full Text] [Related]
15. High expression of truncated GLI3 is associated with poor overall survival in patients with non-small cell lung cancer.
Bai XY; Lin JY; Zhang XC; Xie Z; Yan HH; Chen ZH; Xu CR; An SJ; Sheng GM; Wu YL
Cancer Biomark; 2013; 13(1):37-47. PubMed ID: 23736020
[TBL] [Abstract][Full Text] [Related]
16. Cytoplasmic RAP1 mediates cisplatin resistance of non-small cell lung cancer.
Xiao L; Lan X; Shi X; Zhao K; Wang D; Wang X; Li F; Huang H; Liu J
Cell Death Dis; 2017 May; 8(5):e2803. PubMed ID: 28518145
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA-106b-5p regulates cisplatin chemosensitivity by targeting polycystic kidney disease-2 in non-small-cell lung cancer.
Yu S; Qin X; Chen T; Zhou L; Xu X; Feng J
Anticancer Drugs; 2017 Sep; 28(8):852-860. PubMed ID: 28723865
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of STAT3 expression and its correlation with chemoresistance of non-small cell lung cancer cells.
Yin Z; Zhang Y; Li Y; Lv T; Liu J; Wang X
Acta Histochem; 2012 Feb; 114(2):151-8. PubMed ID: 21549414
[TBL] [Abstract][Full Text] [Related]
19. BCL9 promotes epithelial mesenchymal transition and invasion in cisplatin resistant NSCLC cells via β-catenin pathway.
Zhang Y; Zhang Q; Chen H; Wang C
Life Sci; 2018 Sep; 208():284-294. PubMed ID: 30009824
[TBL] [Abstract][Full Text] [Related]
20. [SIRT1 Influences the Sensitivity of A549 Non-small Cell Lung Cancer Cell Line to
Cisplatin via Modulating the Noxa Expression].
Cao B; He X; Wang W; Shi M
Zhongguo Fei Ai Za Zhi; 2016 Feb; 19(2):57-63. PubMed ID: 26903157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
